Denosumab biosimilar by Sandoz Group for Giant Cell Tumor Of Bone: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Giant Cell Tumor Of Bone.

Pyxis Oncology lays off 20 employees; Xencor’s royalty sale to a pension plan; Jazz partners with MD Anderson

Plus, Celldex prices its public offering and a company developing a UTI vaccine files to go public: Pyxis Oncology to let go of 2o workers:

November 9, 2023

Gut transit time and pH shape microbiome individuality and dietary responses

Scientists reveal gut transit time and pH as key drivers of microbiome and metabolic individuality, paving the way for personalized dietary strategies.

December 2, 2024

Patients in California county may see refunds, debt relief from charity care settlement

California’s largest public hospital plans to start notifying 43,000 former patients Monday that they may be eligible for refunds or billing corrections, part of what

August 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.